Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
Clinical investigation of in-vivo susceptibility of Plasmodium falciparum to artesunate in Xepon Inter-District Hospital, Savannakhet Province, Laos
Acronym
Anredaud
Study hypothesis
The parasite clearance times (PCT) and the efficacy after 2 mg/kg and 4 mg/kg oral artesunate, followed by 3-days artemether-lumefantrine, are not prolonged.
Ethics approval
1. Oxford Tropical Research Ethics Committee (UK) approved on the 8th June 2009 (ref: OXTREC 29-09)
2. Lao PDR National Ethics Committee for Health Research (NECHR) approved on the 18th May 2009 (Ref: 246/NECHR)
Study design
Open randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Plasmodium falciparum malaria, antimalarial drugs
Intervention
Treatment arm 1: oral artesunate 2 mg/kg/day for 3 days followed by oral artemether-lumefantrine (20/120 mg): 1 dose twice daily for three days. Dosing by body weight will be: 1 tablet if less than 15 kg, 2 tablets if 15 - 24 kg, 3 tablets if 25 - 34 kg, and 4 tablets if greater than 35 kg.
Treatment arm 2: oral artesunate 4 mg/kg/day for 3 days followed by oral artemether-lumefantrine (20/120 mg): 1 dose twice daily for three days. Dosing by body weight will be: 1 tablet if less than 15 kg, 2 tablets if 15 - 24 kg, 3 tablets if 25 - 34 kg, and 4 tablets if greater than 35 kg.
The duration of follow-up for both arms is 42 days.
Intervention type
Drug
Phase
Not Applicable
Drug names
Artesunate, artemether-lumefantrine
Primary outcome measure
Number of patients with PCT greater than 72 hours. If six or more patients per treatment group (n = 20) have PCTs greater than 72 hours the trial will be stopped.
Secondary outcome measures
To assess the efficacy of artesunate 2 mg/kg/day and 4 mg/kg/day followed by 3-days artemether-lumefantrine in the treatment of uncomplicated P. falciparum malaria after 42-days follow up. Assessed on the basis of an assessment of the parasitological and clinical outcome of antimalarial treatment according to the latest WHO guidelines.
Overall trial start date
01/06/2010
Overall trial end date
01/10/2010
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Male and female, aged greater than 10 years
2. Female patients between ages of 10 and 12 years old, provided they have not reached menarche, and those who have passed through the menopause
3. Mono-infection with P. falciparum as detected by microscopy
4. Parasitaemia of 10,000 - 175,000/µl asexual forms
5. Presence of axillary or tympanic temperature greater than or equal to 37.5°C or oral or rectal temperature of greater than or equal to 38°C or history of fever during the past 24 hours
6. Ability to swallow oral medication
7. Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule
8. Informed consent from the patient or from a parent or guardian in the case of children
Participant type
Patient
Age group
Other
Gender
Both
Target number of participants
40
Participant exclusion criteria
1. Presence of general danger signs or severe falciparum malaria according to the definitions of the World Health Organization (WHO, 2000)
2. Mixed or mono-infection with another Plasmodium species detected by microscopy
3. Presence of severe malnutrition (defined as a child whose growth standard is below -3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference less than 110 mm)
4. Presence of febrile conditions due to diseases other than malaria or other known underlying chronic or severe diseases
5. Regular medication, which may interfere with antimalarial pharmacokinetics
6. Received antimalarial drugs in the previous 48 hours
7. History of hypersensitivity reactions or contraindications to any of the medicine(s) used
8. Female patients of child-bearing age, defined as those who menstruate or are aged over 12 years and have not reached the menopause
9. Breastfeeding
10. Splenectomy
Recruitment start date
01/06/2010
Recruitment end date
01/10/2010
Locations
Countries of recruitment
Laos
Trial participating centre
Microbiology Laboratory
Vientiane Captial
100
Laos
Sponsor information
Organisation
University of Oxford (UK)
Sponsor details
Churchill Hospital
CCVTM
Headington
Oxford
OX3 7LJ
United Kingdom
Sponsor type
University/education
Website
Funders
Funder type
Research organisation
Funder name
World Health Organization (WHO) (Switzerland)
Alternative name(s)
WHO
Funding Body Type
private sector organisation
Funding Body Subtype
international
Location
Switzerland
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list